WHO ICTRP trial
A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with…
NL-OMON41126 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON41126 |
|---|---|
| Public title | A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors |
| Scientific title | A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors - B1871039 (9002/0235) |
| Primary sponsor | Pfizer |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Phase | 4 |
| Countries | Austria;Belgium;Finland;France;Germany;Italy;Netherlands ;Norway;Spain;Sweden;United States of America |
| Conditions | Ph+ Chronic Myeloid Leukemia; Leukemia;10024324;Ph+ Chronic Myeloid Leukemia; Leukemia |
| Interventions | Patients will receive bosutinib 500 mg orally once daily, preferably in the morning with food. Bosutinib commercial formulation of 100 mg and 500 mg tablets will be provided. ;Bosutinib;Chronic myeloid leukemia;Phase 4;Tyrosine Kinase… |
| Registration date | Nov 14, 2014 |
| Target size | 3 |
| Secondary IDs | 2013-003250-25;NL48222.056.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: